Clozapine administered repeatedly following pretreatment with ketamine enhances dopamine D2 receptors in the dopamine mesolimbic pathway in mice brain. 2019

Marta Szlachta, and Maciej Kuśmider, and Joanna Solich, and Magdalena Kolasa, and Paulina Pabian, and Marta Dziedzicka-Wasylewska, and Agata Faron-Górecka
Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna Street 12, Kraków, 31-343 Poland.

The mechanisms underlying the beneficial effects of clozapine (CLZ) in the treatment of schizophrenia still remains far from clear. In the present work we studied the effect of CLZ on the dopamine D2 receptors (D2R) in the mouse brain. CLZ was administered after ketamine (KET) in a paradigm strictly matching the one used in KET-induced attentional set-shifting task (ASST). It has been shown previously that CLZ reversed KET-induced cognitive impairments. In the present study we used in situ hybridization to estimate the level of mRNA, together with specific D2R radioligand, [3H]domperidone binding in the ventral tegmental area (VTA) as well as in the striatum, and observed an increase in the [3H]domperidone binding in the striatum and an increase in D2R mRNA level in the VTA following repeated (but not acute) CLZ administration in mice pre-treated repeatedly with KET. The obtained results allow for conclusion that CLZ in this experimental paradigm enhances biosynthesis of presynaptic D2R.

UI MeSH Term Description Entries
D007649 Ketamine A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors. 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone,CI-581,Calipsol,Calypsol,Kalipsol,Ketalar,Ketamine Hydrochloride,Ketanest,Ketaset,CI 581,CI581
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D003072 Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment. Overinclusion,Disorder, Cognition,Disorders, Cognition
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012565 Schizophrenic Psychology Study of mental processes and behavior of schizophrenics. Psychology, Schizophrenic

Related Publications

Marta Szlachta, and Maciej Kuśmider, and Joanna Solich, and Magdalena Kolasa, and Paulina Pabian, and Marta Dziedzicka-Wasylewska, and Agata Faron-Górecka
June 1998, European journal of pharmacology,
Marta Szlachta, and Maciej Kuśmider, and Joanna Solich, and Magdalena Kolasa, and Paulina Pabian, and Marta Dziedzicka-Wasylewska, and Agata Faron-Górecka
December 1982, Psychiatry research,
Marta Szlachta, and Maciej Kuśmider, and Joanna Solich, and Magdalena Kolasa, and Paulina Pabian, and Marta Dziedzicka-Wasylewska, and Agata Faron-Górecka
January 1997, Life sciences,
Marta Szlachta, and Maciej Kuśmider, and Joanna Solich, and Magdalena Kolasa, and Paulina Pabian, and Marta Dziedzicka-Wasylewska, and Agata Faron-Górecka
December 2019, Scientific reports,
Marta Szlachta, and Maciej Kuśmider, and Joanna Solich, and Magdalena Kolasa, and Paulina Pabian, and Marta Dziedzicka-Wasylewska, and Agata Faron-Górecka
March 2023, Neuropharmacology,
Marta Szlachta, and Maciej Kuśmider, and Joanna Solich, and Magdalena Kolasa, and Paulina Pabian, and Marta Dziedzicka-Wasylewska, and Agata Faron-Górecka
May 1996, European journal of pharmacology,
Marta Szlachta, and Maciej Kuśmider, and Joanna Solich, and Magdalena Kolasa, and Paulina Pabian, and Marta Dziedzicka-Wasylewska, and Agata Faron-Górecka
August 1989, The Journal of pharmacy and pharmacology,
Marta Szlachta, and Maciej Kuśmider, and Joanna Solich, and Magdalena Kolasa, and Paulina Pabian, and Marta Dziedzicka-Wasylewska, and Agata Faron-Górecka
March 1997, European journal of pharmacology,
Marta Szlachta, and Maciej Kuśmider, and Joanna Solich, and Magdalena Kolasa, and Paulina Pabian, and Marta Dziedzicka-Wasylewska, and Agata Faron-Górecka
January 2022, Frontiers in cellular neuroscience,
Marta Szlachta, and Maciej Kuśmider, and Joanna Solich, and Magdalena Kolasa, and Paulina Pabian, and Marta Dziedzicka-Wasylewska, and Agata Faron-Górecka
February 1998, Psychopharmacology,
Copied contents to your clipboard!